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The High Expression of the microRNA 17–92 Cluster
and its Paralogs, and the Downregulation of the Target
Gene PTEN, Is Associated with Primary Cutaneous
B-Cell Lymphoma Progression
Maxime Battistella1,2,3, Martha Romero1,4, Luis-Jaime Castro-Vega5,6, Guillaume Gapihan1,2,
Fatiha Bouhidel1,2,3, Martine Bagot7,8,9, Jean-Paul Feugeas10 and Anne Janin1,2,3
The oncogenic microRNA (miR) 17–92 cluster has a causative role in the lymphomagenesis of nodal B-cell
lymphomas, by activating proliferation and inhibiting apoptosis. Here we analyzed primary cutaneous B-cell
lymphomas for the miR-17–92 cluster and its paralogs miR-106a-363 and miR-106b-25. In 22 primary cutaneous
diffuse large B-cell lymphomas, leg type (PCLBCL-LT) compared with 22 primary cutaneous follicle center
lymphomas (PCFCLs), we found that miR-20a and miR-106a were overexpressed. Multivariate Cox analysis
showed that higher miR-20a and miR-20b expression levels were associated with shorter disease-free and overall
survival, independently from histological type. Gene expression profiling also showed a downregulation of
8 candidate target genes of miR-20a, miR-20b, and miR-106a in PCLBCL-LT compared with PCFCL. Among
the candidate target genes, PTEN, NCOA3, and CAPRIN2 were confirmed to be underexpressed in PCLBCL-LT
using quantitative reverse transcriptase–PCR on CD20-positive laser-microdissected tumor cells. In multi-
variate Cox analysis, lower PTEN mRNA expression level was associated with shorter disease-free survival
(DFS), independently from the histological type. Altogether, this molecular and bioinformatic study of
44 patient skin biopsy samples showed that the oncogenic miR-17–92 cluster and its paralogs were involved in
cutaneous B-cell lymphoma progression, and that the downregulation of the target gene PTEN was associated
with shorter DFS.
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INTRODUCTION
Cutaneous B-cell lymphomas, accounting for 20–25% of all
primary cutaneous lymphomas (Willemze et al., 2005),
include three main types in the 2005 World Health
Organization-European Organization for Research and
Treatment of Cancer (WHO-EORTC) classification: primary
cutaneous marginal zone B-cell lymphoma, primary cutaneous
follicle center lymphoma (PCFCL), and primary cutaneous
diffuse large B-cell lymphoma, leg type (PCLBCL-LT)
(Willemze et al., 2005). PCLBCL-LT occurs in older patients
and is characterized by centroblastic and immunoblastic cells
expressing Bcl2 and MUM1 (Kodama et al., 2005; Grange
et al., 2007). Gene expression profiling has confirmed that
PCLBCL-LT and cutaneous B-cell lymphomas with large
cleaved centrocytic cells are molecularly distinct, the latter
belonging to PCFCL (Hoefnagel et al., 2005).
Although primary cutaneous marginal zone B-cell lymphoma
and PCFCL are indolent diseases with 98 and 95% of 5-year
survival, respectively (Senff et al., 2007, 2008), relapses after
treatment are frequent, and extracutaneous dissemination
occurs in 5–10% of PCFCL (Senff et al., 2008). PCLBCL-LT
has a more aggressive course, with 41–66% 5-year disease-
specific survival (Grange et al., 2001, 2007, 2014; Senff et al.,
2007). Concerning prognostic factors, the current TNM staging
system for cutaneous B-cell lymphomas is not a reliable
predictor of lymphoma progression (Kim et al., 2007; Senff
and Willemze, 2007). Five clinical studies have shown that
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localization on the leg was associated with poor prognosis in
PCFCL and PCLBCL-LT (Grange et al., 2001, 2007; Kodama
et al., 2005; Smith et al., 2005; Senff et al., 2007), but one
recent study did not confirm this (Grange et al., 2014).
Regarding biological prognostic factors, FoxP1 in situ protein
expression has been linked to poor prognosis in PCFCL but not
in PCLBCL-LT (Senff et al., 2007), and MYD88 L265P muta-
tion was associated with shorter survival in PCLBCL-LT (Pham-
Ledard et al., 2014). To date, these candidate prognostic
markers have not been reproduced and validated prospec-
tively in large independent cohorts of patients.
Recently, the oncogenic role of numerous microRNAs
(miRs) has emerged (Volinia et al., 2006, 2010; Auer, 2011;
Fabbri and Croce, 2011). miRs are small noncoding RNAs that
control the post-translational expression of around 60% of
human protein-coding genes (Friedman et al., 2009). The
miR-17–92 cluster and its paralogs––miR-106a-363, and
miR-106b-25––encode for 13 miRs that act as oncogenes
(He et al., 2005; Mendell, 2008). The miR-17–92 cluster is
overexpressed in systemic lymphomas (Lenz et al., 2008;
Navarro et al., 2009; Thapa et al., 2011; Fassina et al., 2012),
and clinical translational studies have demonstrated the
association between the overexpression of miR-17–92
components and shorter survival in nodal diffuse large B-cell
lymphoma (DLBCL) and mantle cell lymphoma (Alencar et al.,
2011; Rao et al., 2012).
In cutaneous B-cell lymphomas, Koens et al. (2013) per-
formed a pilot study using miR profiling, showing a higher
expression of miR-9–5p, miR-31-5p, miR-129-2-3p, and miR-
214-3p in PCFCL compared with PCLBCL-LT and reporting
the respective abundance of miRs in 19 patients samples. In
30 primary cutaneous marginal zone B-cell lymphoma patients,
low-expression levels of miR-155 and miR-150 were associated
with shorter progression-free survival (Monsalvez et al., 2013).
To date, the association of the miR-17–92 cluster and of its
target genes with tumor progression has not been studied in
cutaneous B-cell lymphomas.
In 44 patients, we characterized the targets of the oncogenic
miR-17–92 cluster and of its paralogs in cutaneous B-cell
lymphomas and assessed whether the expression of these miRs
and their targets was associated with lymphoma progression.
RESULTS
Patients characteristics
The main characteristics of the 22 PCFCL and the 22 PCLBCL-
LT patients are shown in Table 1. Mean age at diagnosis was
significantly older in PCLBCL-LT patients than in PCFCL
patients (Po0.01). First-line treatments were rituximab-poly-
chemotherapy for 59% PCLBCL-LT patients versus radiother-
apy for 54% PCFCL patients. The rates of complete and
partial response to these respective first-line treatments were
significantly lower in PCLBCL-LT patients than in PCFCL
patients (Po0.05). Overall, 27% of PCLBCL-LT patients did
not respond to first-line therapy including chlorambucil
(n¼ 3), radiotherapy (n¼ 1), polychemotherapy without ritux-
imab (n¼ 1), or rituximab only (n¼ 1). Extracutaneous dis-
semination was significantly more frequent in PCLBCL-LT than
in PCFCL (Po0.05). Nevertheless, the rates of relapse or
disease progression were similar in PCLBLC-LT and
PCFCL (P¼0.74). Ten disease-related deaths (45%) were
observed after a mean follow-up of 41.8 months in PCLBCL-
LT patients, whereas only 1 disease-related death occurred in
PCFCL patients after a mean follow-up of 83.7 months
(Po0.01).
miR-106a and miR-20a are differentially expressed in PCFCL and
PCLBCL-LT
In the 44 cutaneous B-cell lymphomas, the 13 miRs of the
miR-17–92 cluster and of its paralogs, miR-106a-363 and
miR-106b-25, were expressed (Table 2). The mean 2–DDCT
fold change value in all lymphoma samples relative to normal
skin was 41 for all miRs except miR-25 (0.98) and miR-93
(0.94). The mean 2–DDCT fold change value in all lymphoma
samples relative to reactive lymph node was 41 only for miR-
92a (Supplementary Table S1 online). Thus, the expression of
11 miRs of the miR-17–92 cluster and its paralogs was higher
in cutaneous B-cell lymphomas compared with normal skin,
and the expression of miR-92a was higher in cutaneous B-cell
lymphomas compared with reactive lymph node.
Comparing the miRs expression in PCLBCL-LT versus
PCFCL samples, using three different calculation methods
(2–DCT method; 2–DDCT method with either normal skin or
lymph node as calibrator), we always found that miR-106a
and miR-20a expression was significantly higher in PCLBCL-
LT than in PCFCL (Table 2 for 2–DDCT method with normal skin
as calibrator; Supplementary Table S1 online for 2–DCT method
and 2–DDCT method with lymph node as calibrator). miR-20b
expression was higher in PCLBCL-LT than in PCFCL (P¼0.07;
P¼0.07; P¼0.06, with the three methods). The expression of
the other 10 miRs (miR-17, miR-18a, miR-18b, miR-19a, miR-
19b, miR-25, miR-92a, miR-93, miR-106b, and miR-363) did
not differ between PCFCL and PCLBCL-LT.
miR-106a, miR-20a, and miR-20b target characterization in
PCFCL and PCLBCL-LT
For miR target characterization, we considered the three more
overexpressed miRs in PCLBCL-LT, miR-106a, miR-20a, and
miR-20b.
We first performed an in silico prediction for target genes of
miR-106a, miR-20a, and miR-20b, using three established miR
target prediction programs: miRanda, DIANA-microT, and
Targetscan (Figure 1). We obtained 2,438 common putative
target genes for miR-106a, 2715 for miR-20a, and 1,419 for
miR-20b.
We also performed protein-coding gene expression profiling
in patients samples, using high-density oligonucleotide micro-
arrays. We detected 12 genes with upregulated mRNA and 53
genes with downregulated mRNA in PCLBCL-LT compared
with PCFCL (false discovery rate o0.001). (Supplementary
Table S2 online).
The final comparison of the in silico predicted miR target list
and of the 53 downregulated gene list enabled us to identify a
signature of eight miR target genes effectively downregulated
in PCLBCL-LT versus PCFCL. They were PTEN, CAPRIN2,
NCOA3, MICB, CYP4V2, PLA2G6, TTC7A, and MLLT6
(Supplementary Table S1 online, bold genes).
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Targets mRNA and protein expression in PCFCL and PCLBCL-LT
As specific human cutaneous B-cell lymphoma lines are
currently lacking for in vitro target validation, we studied
further the four genes already validated in vitro as targets for
miR-106a, miR-20a, or miR-20b––i.e., PTEN for miR-20a
(Trompeter et al., 2011), CAPRIN2 for miR-20a and miR-
106a (Riley et al., 2012), NCOA3 for miR-20b (Castellano
et al., 2009), and MICB for miR-20a (Stern-Ginossar et al.,
2008).
Using quantitative real-time reverse-transcriptase–PCR of
microdissected CD20-positive lymphoid tumor cells, the
relative expression levels of PTEN, CAPRIN2, and NCOA3
mRNA were significantly lower in PCLBCL-LT than in PCFCL
(0.51 vs. 1.15, Po0.05; 0.69 vs. 1.11, Po0.05; 7.1 vs. 15,
Po0.01, respectively), thus confirming the findings from gene
expression microarrays. This was not the case for MICB mRNA
(0.05 vs. 0.06, P40.05; Figure 2a).
Using in situ immunostainings, we were able to analyze
PTEN and MICB protein expression in 89 and 93% of the
cases and NCOA3 protein expression in 66% of the cases. No
reliable immunostaining was obtained for CAPRIN2 protein
using commercially available antibodies. The detailed results
of the immunohistochemical analyses are shown in
Supplementary Table S2 online. The intensity and the dis-
tribution of PTEN, NCOA3, or MICB protein expression in the
tumor cells were not statistically different in PCLBCL-LT and
PCFCL, when considering all samples stained. NCOA3 protein
expression was lost in 5% PCLBCL-LT samples and 5% PCFCL
samples. MICB protein expression was lost in more PCLBCL-
LT samples (73%) than PCFCL samples (41%), but the
difference did not reach statistical significance (P¼ 0.08).
Table 1. Characteristics of the patients
PCLBCL-LT
(n¼22)
PCFCL
(n¼ 22)
Statistical
comparison (P)
Sex (M/F) 13/9 17/5 0.33
Mean age (years) 74.8 (42–102) 59.7 (32–84) o0.01
First-line treatment
 Radiotherapy 2 (9%) 12 (54%)
 Chlorambucil 3 (14%) 3 (14%)
 Polychemotherapy 2 (9%) 2 (9%)
 Rituximab (R) 2 (9%) 3 (14%)
 R-polychemotherapy 13 (59%) 2 (9%)
Response to first-line treatment
 Complete response 14 (64%) 21 (95%)
 Partial response 2 (9%) 1 (5%)
 No response 6 (27%) 0 (0%) o0.05
Patients with relapse or
disease progression
17 (73%) 15 (68%) 0.74
Extracutaneous
dissemination
10 (45%) 2 (9%) o0.05
Mean follow-up time
(months)
41.8 (6–107) 83.7 (12–271) o0.05
Status at last follow-up
 Alive with complete
response
7 (32%) 17 (77%)
 Alive with disease 5 (23%) 4 (18%)
 Died of disease 10 (45%) 1 (5%) o0.01
Abbreviations: PCFCL, primary cutaneous follicle center lymphoma;
PCLBCL-LT, primary cutaneous large B-cell lymphoma—leg type. Bold
values signify at Po0.05.
Table 2. Mean 2 DDCT fold change values of the 13 miRs in cutaneous B-cell lymphomas
miR All samples (n¼44) PCLBCL-LT (n¼ 22) PCFCL (n¼ 22)
Statistical comparison
PCLBCL-LT versus
PCFCL (Wilcoxon test; O)
miR-17 1.62±1.10 1.84±1.34 1.18±0.74 0.14
miR-18a 3.07±3.24 4.05±4.08 2.03±1.55 0.10
miR-18b 1.36±1.73 1.62±1.94 1.10±0.81 0.25
miR-19a 1.34±2.21 1.97±2.78 0.71±0.83 0.24
miR-19b 1.39±1.43 1.72±1.80 0.95±0.49 0.76
miR-20a 3.35±2.39 4.89±2.77 1.07±1.00 o0.0001
miR-20b 2.61±4.39 4.03±5.35 0.97±0.61 0.07
miR-25 0.98±0.64 0.78±0.45 1.20±0.75 0.10
miR-92a 1.84±3.13 1.96±4.07 1.72±1.68 0.40
miR-93 0.94±0.83 0.89±0.78 0.99±0.91 0.72
miR-106a 4.14±5.28 5.90±6.56 1.70±2.74 o0.01
miR-106b 1.82±1.00 1.81±1.03 1.84±1.04 0.94
miR-363 2.24±2.81 2.82±3.70 1.60±1.21 0.93
Abbreviations: miR, microRNA; PCFCL, primary cutaneous follicle center lymphoma; PCLBCL-LT, primary cutaneous large B-cell lymphoma—leg type.
Calibration, healthy donor skin samples; endogenous controls, RNU24 and RNU44 small nucleolar RNAs. The normalization of the miR expression to the two
endogenous controls RNU24 and RNU44 was done using the geometric mean method using Bio-Rad CFX software. Results are shown as mean±SD. Bold
values signify at Po0.09.
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miR-106a and miR-20a expression was higher in the cases
with MICB protein loss compared with the cases with MICB
protein expression, although the difference did not reach
statistical significance (5.62 vs. 2.73, P¼0.06; 4.57 vs. 2.39,
P¼0.07, respectively).
A total loss of PTEN (phosphatase and TENsin homolog)
protein expression was found in seven PCLBCL-LT (32%) and
six PCFCL (27%) patients. Remarkably, miR-106a and miR-
20a expression was significantly higher in the cases with PTEN
protein loss compared with the cases with PTEN protein
expression (Po0.01 for both; Figure 2b).
Altogether, the results strengthened the hypothesis of a
regulatory effect of miR-20a and miR-106a on MICB and
PTEN in cutaneous B-cell lymphomas.
miR-20a, miR-20b, and PTEN mRNA are related to tumor
progression in PCFCL and PCLBCL-LT
Regarding protein expression, the miR targets PTEN, NCOA3,
and MICB were not associated with either disease-free survival
(DFS) or overall survival (OS; P40.05) using Kaplan–Meier
curves with the log-rank test (see Supplementary Figure S1
online for DFS and OS according to PTEN protein status). For
mRNA gene expression, no significant association with DFS or
OS was found for CAPRIN2, NCOA3, and MICB. However,
PTEN mRNA gene expression level was associated with
DFS (Po0.05) but not with OS (P40.05) using the Cox
univariate hazard model. It was again associated with DFS
(Po0.05) but not with OS (P¼0.19), independently from
the histological type, using the Cox multivariate hazard
model. A multiple correspondence analysis also confirmed
that shorter DFS (o37 months), low PTEN mRNA expression
level, and PCLBCL-LT histotype were closely related variables
(Figure 3).
Using Kaplan–Meier curves with the log-rank test, DFS was
significantly better in PCFCL (56 months IC95% (45, not
determined)) than in PCLBCL-LT (9 months IC95% (1–28))
(Po0.00001). OS was also significantly better in PCFCL than
PCLBCL-LT (Po0.01) (Figure 4a).
Kaplan–Meier curves were then plotted for DFS and OS
according to ‘‘low’’ or ‘‘high’’ levels for miR-20a and miR-
20b, after discretization of the miR-20a and miR-20b expres-
sion levels using Fisher’s algorithm (Figure 4b). Three groups
of patients were considered: ‘‘miR-20a low and miR-20b low’’
(n¼ 18; four PCLBCL-LT and 14 PCFCL); ‘‘either miR-20a high
or miR-20b high’’ (n¼ 13; nine PCLBCL-LT and four PCFCL);
and ‘‘miR-20a high and miR-20b high’’ (n¼ 13; 10 PCLBCL-
LT and three PCFCL). Using the log-rank test, the three groups
had significantly different DFS (Po0.0001) and OS (Po0.05),
with the ‘‘miR-20a low and miR-20b low’’ patients having the
longest DFS and OS. Kaplan–Meier curves were also plotted
for DFS and OS according to ‘‘low’’ or ‘‘high’’ levels for miR-
106a, after discretization of the expression levels using Fisher’s
algorithm (Supplementary Figure S2 online). The 20 ‘‘miR-106
high’’ patients (14 DLBCL, six PCFCL) had significantly shorter
DFS (Po0.001) and OS (Po0.01) than the 24 ‘‘miR-106 low’’
(eight DLBCL, 16 PCFCL) patients.
Using the Cox univariate hazard model, DFS was signifi-
cantly associated with miR-106a, miR-20a, and miR-20b
expression (Po0.01; Po0.0001; Po0.01, respectively), but
OS was associated only with miR-20a and miR-20b (Po0.05;
Po0.01, respectively). Using the Cox multivariate hazard
model, DFS and OS were both associated with miR-20a and
miR-20b expression, independently from the histological type
(PCLBCL-LT or PCFCL) (Po0.0001 for DFS; Po0.01 for OS).
Altogether, in this series of 44 cutaneous B-cell lymphomas,
we found three molecular markers related to survival,
In silico target prediction for 
miR106a, miR20a and miR20b
Protein-coding
gene expression profiling
in patients samples
PCLBCL-LT
up regulated mRNAs
PCLBCL-LT
samples
PCFCL
samplesRosetta resolver
FDR<0.001
Common gene list
Target gene signature
miRNAs targets
effectively down regulated
in PCLBCL-LT samples
PCLBCL-LT
down regulated mRNAs
Common predicted
miRNA target list
Targetscan
database
DianamicroT
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miRanda
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Figure 1. Strategy of miR target characterization for miR-106a, miR-20a, and miR-20b in cutaneous B-cell lymphomas. In silico target prediction was combined
with gene expression profiling in patients samples to generate a signature of predicted target genes that were effectively downregulated at the mRNA level in
PCLBCL-LT versus PCFCL. miR, microRNA; PCFCL, primary cutaneous follicle center lymphoma; PCLBCL-LT, primary cutaneous large B-cell lymphoma, leg type.
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independently from the histological type. miR-20a, miR-20b,
and PTEN mRNA were related to DFS, whereas miR-20a and
miR-20b were associated with OS.
DISCUSSION
In this molecular and bioinformatics study performed on skin
biopsy samples from 44 patients with cutaneous B-cell
lymphomas, we found an overexpression of all the miRs of
the oncogenic miR-17–92 cluster in cutaneous lymphomas
compared with normal skin, whereas miR-92 was overex-
pressed in cutaneous lymphomas compared with reactive
lymph node. In the pilot study by Koens et al. (2013), 3 of
these miRs had also been identified in the 30 most abundantly
expressed miRs in 19 PCLBCL-LT and PCFCL.
Experimental data have deciphered the function of miR-17–
92 cluster in lymphomas. In a mouse model of nodal B-cell
lymphoma, the forced expression of the miR-17–19b-1 cluster
(a miR-17–92 variant) accelerated lymphoma onset and
progression (He et al., 2005). The oncogenic role of the
miR-17–92 cluster was confirmed, as a higher expression
of the miR-17–92 cluster in transgenic mice increased
proliferation and decreased apoptosis in lymphoma cells
(Xiao et al., 2008). In vitro studies in human B-cell
lymphoma cell lines showed that the miR-17–92 cluster, in
addition to its effect on proliferation and apoptosis (He et al.,
2005; Inomata et al., 2009), was able to induce resistance to
radiotherapy (Jiang et al., 2010) and chemotherapy (Rao et al.,
2012).
The oncogenic miR-17–92 cluster (located on chromosome
13) has two known paralogs––miR-106a-363 (on chromosome
X) and miR-106b-25 (on chromosome 7). The three clusters
act in functional synergy (Mogilyansky and Rigoutsos, 2013).
Even if intercluster and intracluster redundancy is observed,
each miR in the three clusters has its own functional
importance (Mendell, 2008; Mogilyansky and Rigoutsos,
2013). Five miRs of the paralogs were overexpressed in our
44 cutaneous B-cell lymphomas, including members of the
miR-106a-363 paralog cluster, usually undetectable in normal
tissues (Ventura et al., 2008).
In the only other study on miRs in PCLBCL-LT and PCFCL,
using a different methodology based on miR profiling with
high-throughput sequencing, the authors found miR-106a
among the 30 miRs most abundantly expressed in 19
cutaneous B-cell lymphomas, in accordance with our results
(Koens et al., 2013). When they compared PCLBCL-LT and
PCFCL samples using single quantitative real-time reverse-
transcriptase–PCR, they found miR-9–5p, miR-31-5-p, miR129-
2-3p, and miR-214-3p underexpressed in PCFCL. Here, using
single quantitative real-time reverse-transcriptase–PCR, miR-
106a, and mir-20a were significantly more expressed in 22
PCLBCL-LT than in 22 PCFCL.
For the 3 miRs that were the more overexpressed in
PCLBCL-LT compared with PCFCL, we combined bioinfor-
matics and molecular techniques to characterize the miR
targets (Akbari Moqadam et al., 2013). The combination of
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Figure 3. PTEN mRNA is associated with disease-free survival in cutaneous
B-cell lymphomas. Multiple correspondence analysis factor map examining
statistical associations between the following nominal variables: histological
type (PCLBCL-LT versus PCFCL), Disease-free survival (437 months versus
o37 months), and PTEN, CAPRIN2, NCOA3, or MICB mRNA expression
levels (high or low). For this, PTEN, CAPRIN2, NCOA3, and MICB mRNA
expression levels were discretized in ‘‘low’’ or ‘‘high’’ values using Fisher’s
algorithm. Low PTEN mRNA, PCLBCL-LT, and DFS o37 months are closely
related variables (blue box), whereas high PTEN mRNA, PCFCL, and DFS 437
months are also closely related variables (green ellipse). DFS, disease-free
survival; MICB, major histocompatibility complex class I-related chain B;
PCFCL, primary cutaneous follicle center lymphoma; PCLBCL-LT, primary
cutaneous large B-cell lymphoma, leg type.
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gene expression profiling and in silico target prediction
enabled us to find a signature of eight target genes down-
regulated in PCLBCL-LT versus PCFCL.
We focused on PTEN, CAPRIN2, NCOA3, and MICB, the
four target genes for which direct regulation by one of the
three miRs had already been experimentally proven (Stern-
Ginossar et al., 2008; Castellano et al., 2009; Trompeter et al.,
2011; Rao et al., 2012; Riley et al., 2012), because no specific
cutaneous B-cell lymphoma human cell line was available for
functional studies to test the direct regulation of the eight
target genes by the three miRs.
The protein loss of MICB (major histocompatibility complex
class I-related chain B) was seen in 73% PCLBCL-LT and 41%
PCFCL samples, and it was associated with an increase in
miR-20a and miR-106a expression levels, in favor of a
regulatory effect. MICB protein loss may be associated with
resistance to NK-cell cytotoxicity in cutaneous B-cell lym-
phoma. Indeed, the expression loss of MICA and ULBP, two
other NKG2D ligands, increases B-cell lymphoma cell lines
resistance to NK-cell cytotoxicity (Pende et al., 2002), and the
expression loss of MICB also induces resistance to NK-cell
cytotoxicity in B-cell acute lymphoblastic leukemia (Romanski
et al., 2005) and in epithelial cancer cell lines (Tsukerman
et al., 2012).
PTEN protein, a major tumor suppressor, was lost in about
one-third of PCLBCL-LT and PCFCL. A similar PTEN protein
loss was reported in 37–55% of patients with nodal DLBCL
(Liu et al., 2010; Pfeifer et al., 2013). In our cutaneous B-cell
lymphoma samples, PTEN protein loss was associated with
higher miR-20a and miR-106a expression levels, indicating
possible direct regulation of PTEN through miR—30 untrans-
lated region mRNA interaction. Among the miRs of the miR-
17–92 cluster and paralogs, the direct targeting of the PTEN 30
untranslated region has been demonstrated experimentally for
miR-17, miR-19a, miR-19b, miR-92a, miR106b, and miR-20a
(Gottwein et al., 2011; Trompeter et al., 2011; Zhu et al.,
2014) but not yet for miR-106a.
The frequency of PTEN protein loss was not different in
PCLBCL-LT and PCFCL, although miR-20a and miR-106a
expression was different in these two groups, and although
PTEN mRNA was lower in PCLBCL-LT than in PCFCL. The
complex regulation of the protein output by miRs, not
similarly affecting mRNA and protein, may explain these
results (Baek et al., 2008; Vogel and Marcotte, 2012). We
can also hypothesize that PTEN loss occurred differently in
some PCFCL, either through mutation, loss of heterozygosity,
or promoter methylation (Song et al., 2012). The limitation of
the cohort size may also be implicated in these results.
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Figure 4. miR-20a and miR-20b expression is associated with disease-free and overall survival (OS) in cutaneous B-cell lymphomas. Prognostic factors for
disease-free survival (DFS) and OS. (a) Kaplan–Meier curves for DFS and OS according to histological type (PCLBCL-LT versus PCFCL). (b) Kaplan–Meier curves for
DFS and OS examining the significance of high versus low-expression levels of miR-20a and miR-20b.miR, microRNA; PCFCL, primary cutaneous follicle center
lymphoma; PCLBCL-LT, primary cutaneous large B-cell lymphoma, leg type.
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In a miR-17–92 transgenic mouse model (Jin et al., 2013)
and in xenografts of mantle cell lymphoma cell lines with
conditional knock-down of miR-17–92 (Rao et al., 2012),
PTEN downregulation induced B-cell lymphoma progression
and was responsible for the constitutive activation of PI3K/
AKT pathway. On the basis of PTEN protein loss, a subtype of
PI3K/AKT-pathway-dependent nodal DLBCL has been
characterized (Pfeifer et al., 2013), with selective sensitivity
of PTEN-deficient DLBCL models to PI3K inhibition by the
pan-PI3K inhibitor LY294002 (Pfeifer et al., 2013). The
pharmacological inhibition of PI3K (Westin, 2014) might
thus provide a promising therapeutic approach in PTEN-
deficient cutaneous B-cell lymphomas.
In human nodal DLBCL and mantle cell lymphoma, clinical
translational studies have demonstrated the relationship
between the overexpression of miR-17–92 cluster components
and shorter survival, i.e., miR-18a in human nodal DLBCL
(Alencar et al., 2011) and C13orf25, the primary transcript
from which the miR-17–92 cluster is processed, in human
mantle cell lymphoma (Rao et al., 2012). In our 44 human
cutaneous B-cell lymphoma patients, both miR-20a and
miR-20b were identified as factors related to disease pro-
gression, independently from the histological type. miR-106a
expression was also associated with OS and DFS in Kaplan–
Meier analysis but was not an independent predictive variable
in multivariate analysis. Shorter OS and DFS were clearly
associated with higher expression levels of miR-20a and miR-
20b. A similar association of miR-20a expression level with
prognosis has been reported so far only in colon cancer
(Zhang et al., 2013).
Altogether, the expression levels of miR-20a and miR-20b,
members of the miR-17–92 cluster and paralogs, and the
expression levels of PTEN mRNA were associated with cuta-
neous B-cell lymphoma progression. High miR-20a and miR-
20b expression emerged as negative prognostic factors related
to shorter disease-free and OS in PCFCL and PCLBCL-LT.
MATERIALS AND METHODS
Patients and samples
Forty-four patients with primary cutaneous B-cell lymphoma from a
single center (Hoˆpital Saint-Louis, Paris, France), diagnosed between
2000 and 2007, were included in the study. Twenty-two had
PCLBCL-LT and 22 had PCFCL. All skin biopsies were performed
before treatment. Diagnoses were reviewed by two pathologists (MB,
AJ) according to the latest WHO-EORTC classification for cutaneous
lymphomas (Burg et al., 2005; Willemze et al., 2005) and the WHO
2008 classification (Swerdlow et al., 2008). The tumor cell per-
centage was at least 80% in each tumor biopsy sample. Treatment
and follow-up data were retrospectively collected. DFS was defined
as the time-lapse from first complete response to disease relapse. DFS
was considered as null when patients had no complete response to
treatment. OS was defined as the time from diagnosis to death or last
follow-up.
Ten healthy donor skin samples, obtained from plastic surgery
pieces, and 10 reactive lymph node samples were used as controls.
Skin and lymph node samples were formalin fixed and paraffin
embedded and snap frozen. The skin and lymph node biopsies were
performed for diagnostic purpose. Patients and healthy donors were
informed that part of the material remaining after the diagnosis had
been established could be used for research and gave written
informed consent in accordance with the Helsinki declaration. The
study was approved by the institutional review board of Hoˆpital Saint-
Louis (Paris, France).
Quantification of miR expression
Total RNA (including miR) was extracted from ten 20mm-thick paraffin
tissue sections using the RecoverAll total nucleic-acid isolation kit
(Ambion, Cambridgeshire, UK). RNA quality was controlled for by the
spectrometric assay (Nanodrop ND-1000, Thermo Scientific, Wil-
mington, DE). The expression of miR-17, miR-18a, miR-18b, miR-19a,
miR-19b, mir-20a, miR-20b, miR-25, miR-92a, miR-93, miR-106a,
miR-106b, and miR-363 from the miR-17–92 and its paralog clusters
was analyzed using reverse quantitative PCR with a miR-reverse-
transcription-kit (Applied Biosystems, Darmstadt, Germany) and cor-
responding hsa-miR assays for each miR (all from Applied Biosystems).
The quantitative reverse transcriptase in real time–PCR was carried out
on the Bio-Rad CFX96 Real-Time Detection System (Bio-Rad, Her-
cules, CA). RNU24 and RNU44 were used as endogenous controls.
Healthy donor skin samples or lymph node samples were used for
calibration. A relative quantification was performed using the 2–DCT
method and using the 2–DDCT method, with normalization of the miR
expression to the 2 endogenous controls using the geometric mean
method (Bio-Rad CFX Manager software, Bio-Rad).
mRNA gene expression profiling
Total RNA was extracted from ten 20mm-thick frozen tissue sections
using Rneasy minikit (Qiagen, Courtaboeuf, France). RNA integrity
was checked using Agilent 2,100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA). All RNA samples had RNA integrity numbers between
7.7 and 10.
RNA labeling, microarray hybridization, and scanning were per-
formed according to Pennartz et al. (2004). 100 ng of total RNA were
amplified and labeled using the Agilent Low Input Quick Amp
Labeling kit (Agilent Technologies) and then hybridized overnight in
Agilent Whole-Human genome Oligo Microarrays 8x60k, using the
Agilent Gene Expression Hybridization kit (Agilent Technologies).
Washing and scanning steps were carried out using Agilent Gene
Expression Wash buffer and Agilent Microarray Scanner System
(Agilent Technologies). Full microarray data compliant with the
MIAME guidelines are available on Gene Expression Omnibus
(www.ncbi.nlm.nih.gov/geo/, accession number GSE55833). The
intensity profile for each probe set was calculated using Agilent
Feature Extraction Software (Agilent Technologies). Differential gene
expression was calculated using the Rosetta Resolver gene expression
data analysis system (Rosetta Biosoftware, Seattle, WA) to identify
genes with statistically significant changes in expression between
PCLBCL-LT and PCFCL. The ratios were calculated by dividing
sample signal intensity by control signal intensity, using PCLBCL-LT
specimens as samples, and PCFCL specimens as controls.
miR target prediction and comparison with gene expression data
Target prediction in silico was carried out using three miR target
prediction tools: TargetScan, DIANA-microT, and miRanda. Targets
predicted by all three tools were considered for further analyses.
As an inverse correlation between expression levels of miRs and
mRNAs indicates potential miR targets degraded upon miR–mRNA
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bindings, we considered that low mRNA levels were indicative of
targets regulated by overexpressed miRs (Akbari Moqadam et al.,
2013). We thus focused on miRs overexpressed in PCLBCL-LT
compared with PCFCL and aimed to characterize their targets. We
used both in silico prediction and gene expression profiling, where
we only considered the genes significantly downregulated in
PCLBCL-LT compared with PCFCL with a false discovery rate
o0.001 (Figure 1).
Analyses of PTEN, NCOA3, CAPRIN2, and MICB expression
Quantification of mRNA expression. Using a PALM Microbeam/
Zeiss system (Carl Zeiss, Oberkochen, Germany), laser-micro-
dissection of lymphoid tumor cells was performed on seven-mm
thick frozen sections stained with FITC-labeled anti-CD20
antibody (rabbit polyclonal antibody; Biorbyt, Cambridge, UK).
Total RNA was extracted from microdissected tumor cells using
the RNeasy minikit (Qiagen) and was converted to cDNA
using the GoScript Reverse transcription system (Promega,
Madison, WI). Expression of PTEN (Hs00829813_s1, Applied
Biosystems), NCOA3 (Hs01105251_m1, Applied Biosystems),
CAPRIN2 (Hs00225069_m1, Applied Biosystems), and MICB
(Hs04187752_mH, Applied Biosystems) was analyzed on a Bio-
rad CFX96 Real-Time Detection System (Bio-Rad), using human
transcription factor IID/TATA-binding protein (Hs99999910_m1,
Applied Biosystems) as the endogenous control. A relative
quantification to TATA-binding protein was performed using the
2–DCT method.
Analysis of in situ protein expression. PTEN, CAPRIN2, NCOA3,
and MICB expression was assessed on 4-mm thick paraffin
sections using automated indirect immunoperoxydase staining
(Benchmark XT; Roche Diagnostics, Basel, Switzerland). Anti-
human PTEN mouse antibody (clone 6H2.1, Dako, Glostrup,
Denmark), anti-human CAPRIN2 polyclonal rabbit antibody
(HPA039746, Sigma-Aldrich, St Louis, MO), anti-human NCOA3
polyclonal rabbit antibody (HPA024210, Sigma-Aldrich), and
anti-human MICB rabbit antibody (bs-6933R, Bioss, Woburn,
MA) were used as the primary antibodies. Controls systematically
included absence of primary antibody and use of an irrelevant
antibody of the same isotype. Pathological analyses of the
intensity and distribution of the expression of the four proteins
were performed independently by two pathologists blinded to
diagnosis and clinical data (MB, AJ).
Statistics
The statistical tests were performed using R version 3.0.1 statistical
software (R-Foundation for Statistical Computing, Vienna, Austria).
Using the Kaplan–Meier curve and the log-rank test, DFS and OS were
analyzed for PCLBCL-LT versus PCFCL. miRs, mRNA, and protein
relative quantities were compared in PCLBCL-LT versus PCFCL using
the Wilcoxon test. Then, using a Cox proportional hazard regression
model, univariate and multivariate analyses were performed to identify
miR, mRNA, or protein expression associated with DFS or OS (survival
R package, The R Foundation, Wien, Austria). miR-20a and miR-20b
expression levels were discretized in ‘‘high’’ and ‘‘low’’ values using
Fisher’s algorithm (classInt R package). Kaplan–Meier curves were
plotted with DFS or OS as the outcome, checking the significance of
high versus low values of miR-20a and miR-20b, using the log-rank test.
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